On November 26, 2019 BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, reported that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Piper Jaffray 31st Annual Healthcare Conference being held December 3 – 5, 2019 in New York City (Press release, BioXcel Therapeutics, NOV 26, 2019, View Source [SID1234551722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Tuesday, December 3, 2019
Time: 11:50 a.m. – 12:10 p.m. ET

A live webcast of the presentation and the accompanying presentation materials that will be discussed will be accessible through the Investors section of the company’s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.

On November 26, 2019 Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that management will present in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. ET in New York (Press release, Bicycle Therapeutics, NOV 26, 2019, View Source [SID1234551721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.

On November 26, 2019 Delta-Fly Pharma, Inc. (TOKYO: 4598) reported that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927 (Press release, Delta-Fly Pharma, NOV 26, 2019, View Source [SID1234551720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed Acute Myelogenous Leukemia. A Phase 3 clinical study at MD Anderson Cancer Center in Texas, USA and other sites in the USA is underway.
Two patients at UT Southwestern Medical Center in Texas and Banner MD Anderson Cancer Center in Arizona registered for this study in November 2019.

In addition, a Phase 1 clinical study of DFP-14927, the polymeric delivery of DFP-10917 in patients with advanced solid tumors has been initiated at MD Anderson Cancer Center.
Two patients registered for this study in October of this year and treatment is ongoing.

Company’s profile

Company name

Delta-Fly Pharma, Inc. [TOKYO:4598]

Capital

2849 million Japanese Yen

Name and Title of Representative

Kiyoshi Eshima, PhD, President

Date of Incorporation

December 6, 2010

Description of Business

Research and development, manufacturing and marketing of pharmaceuticals

Head Office

37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan

Branch Office

Tokyo, Beijing, Vancouver

On November 26, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 1:30 p.m. Eastern Time in New York, NY (Press release, OncoSec Medical, NOV 26, 2019, View Sourcepress-releases/detail/2014/oncosec-to-present-at-the-31st-annual-piper-jaffray" target="_blank" title="View Sourcepress-releases/detail/2014/oncosec-to-present-at-the-31st-annual-piper-jaffray" rel="nofollow">View Source [SID1234551719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of OncoSec’s website at View Source, where it will be archived for approximately 30 days.

On November 26, 2019 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, reported that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor conferences in December (Press release, Aeglea BioTherapeutics, NOV 26, 2019, View Source [SID1234551718]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI 2nd Annual HealthCONx Conference
Date: Tuesday, December 3, 2019
Presentation Time: 8:45 a.m. ET
Location: Boston, MA

Piper Jaffray 31st Annual Healthcare Conference
Date: Wednesday, December 4, 2019
Presentation Time: 4:30 p.m. ET
Location: New York, NY

Live-streaming webcasts of these presentations will be available on the Presentations & Events section of the Aeglea BioTherapeutics investor relations website.